Industry News

Kimera® Labs Files First FDA Investigational New Drug (IND) Application Using Exosomes for Treatment of ARDS Secondary to COVID-19

exosomes

Kimera Labs, a privately held clinical stage biotechnology company, announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera’s first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes.  ...

Read More »